Statements (53)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Company
|
| gptkbp:activeDuring |
gptkb:bromfenac_sodium
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:brand |
gptkb:Xibrom
Bromday |
| gptkbp:chemicalFormula |
C15H13BrN2O3S
arylpropionic_acid_derivative |
| gptkbp:clinicalTrials |
Phase III
ophthalmology |
| gptkbp:contraindication |
headache
blurred vision severe liver disease dry eye active peptic ulcer foreign body sensation hypersensitivity_to_bromfenac |
| gptkbp:developedBy |
gptkb:Bausch_+_Lomb
|
| gptkbp:dosageForm |
solution
|
| gptkbp:drugInterdiction |
anticoagulants
other NSAIDs antihypertensives |
| gptkbp:formulation |
0.09% solution
|
| gptkbp:gestationPeriod |
C
|
| gptkbp:hasAwards |
unknown
|
| gptkbp:healthcare |
store at room temperature
avoid contact with eyes safety not established do not use if allergic to NSAIDs report any severe eye pain |
| https://www.w3.org/2000/01/rdf-schema#label |
bromfenac
|
| gptkbp:isATypeOf |
119366-45-3
|
| gptkbp:issuedBy |
eye drops
|
| gptkbp:lastProduced |
2005
|
| gptkbp:mandates |
postoperative inflammation
pain after cataract surgery |
| gptkbp:marketedAs |
gptkb:Canada
gptkb:European_Union gptkb:United_States |
| gptkbp:numberOfStudents |
1-2 hours
|
| gptkbp:nutritionalValue |
liver
|
| gptkbp:packaging |
bottle
|
| gptkbp:route |
topical
|
| gptkbp:safetyFeatures |
generally well tolerated
|
| gptkbp:sideEffect |
stinging
eye irritation burning sensation redness of the eye |
| gptkbp:storage |
room temperature
|
| gptkbp:triggerType |
inhibits cyclooxygenase enzymes
|
| gptkbp:usedFor |
treating inflammation
treating pain |
| gptkbp:waterManagement |
urine
|
| gptkbp:weight |
365.24 g/mol
|